Roche

What Roche does

Produtos Roche Químicos e Farmacêuticos S.A. is the Brazilian operating entity of the Swiss-headquartered Roche Group, headquartered at Av. Engenheiro Billings, 1729 in São Paulo, with a separate corporate office at Rua Dr. Rubens Gomes Bueno, 691 in Várzea de Baixo. The company runs three core businesses in Brazil through wholly-owned subsidiaries: Roche Farma Brasil (pharmaceuticals), Roche Diagnóstica Brasil (in-vitro diagnostics), and Roche Diabetes Care Brasil (Accu-Chek). Its pharmaceutical portfolio spans oncology, immuno-oncology, neuroscience, rare diseases (including spinal muscular atrophy via Evrysdi and hemophilia A via Hemcibra), and ophthalmology (Vabysmo), with named brands such as Actemra, Alecensa, Avastin, Ocrevus, Herceptin, Tecentriq, Enspryng, and Phesgo. Roche serves healthcare professionals, healthcare institutions (hospitals, clinics, laboratories), and patients, addressing unmet needs across multiple therapeutic areas with a stated pipeline of 110+ complex molecules under development.

The technology backbone combines pharmaceutical R&D with diagnostic capabilities under a personalized-medicine strategy, complemented by the Accu-Chek diabetes care franchise. The most technically differentiated asset is the Accu-Chek SmartGuide AI-enabled continuous glucose monitoring (CGM) solution, which received CE Mark approval in July 2024 for adults with type 1 and type 2 diabetes on flexible insulin therapy; its predictive algorithms forecast hypoglycemia risk within 30 minutes, predict glucose levels over two hours, estimate nocturnal hypoglycemia risk, and demonstrated 9.2% MARD accuracy. AI is also applied to pathology diagnostics (anomaly detection, treatment planning, drug discovery) and to real-world data initiatives such as the Roche Farma RWD Latam Initiative. Sub-brands such as Roche Dialogo (medical-scientific portal), Portal de Pacientes, Mulher Consciente, Visionaries, and Conexão Roche extend the platform into HCP and patient engagement.

Roche's revenue model is sales-led and B2B, operating through four channels: direct sales to hospitals and clinics, pharmacy and licensed distributor networks, public procurement (licitações) with dedicated bid management, and inside-sales direct customer service for Accu-Chek via 0800 772 0126. Pharmaceutical pricing in Brazil is regulated by CMED (Câmara de Medicamentos do Ministério da Saúde), and Roche sells only to legal entities (pharmacies, hospitals, distributors), not directly to patients. Distribution is supported by 0800 medical information, pharmacovigilance, and customer service lines, plus dedicated HCP and patient portals. The company has no parent within the provided Brazil-specific data and is the local representation of the globally listed Roche Holding AG (SIX: ROG).

Name

Roche

Legal name

Produtos Roche Químicos e Farmacêuticos S.A.

Website

https://roche.com.br

Company type

Public

Founded year

1896

Operating status

Operating

Headcount range

1–10 employees

Short description

Produtos Roche Químicos e Farmacêuticos S.A. operates Roche's Brazilian pharmaceutical operations, supplying oncology, neuroscience, rare-disease, ophthalmology, and immunology medicines alongside Accu-Chek diabetes care products and diagnostic solutions to hospitals, pharmacies, healthcare professionals, and public-sector buyers in Brazil.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), In-Vitro Diagnostic Substance Manufacturing (325413), Surgical Appliance and Supplies Manufacturing (339113), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Oncology Specialty Pharmaceuticals (HLAIACAA)

akta.pro secondary industries

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH)

Keywords

• Pharmaceutical products
• Diagnostic solutions
• Diabetes care
• Oncology medicines
• Personalized healthcare

Headquarters

HQ city

São Paulo

HQ country

Brazil

HQ region

Latin America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

1. Pharmaceutical Products: Roche develops and sells innovative medicines for unmet medical needs in oncology, immuno-oncology, neuroscience, rare diseases, and ophthalmology. Revenue generated through direct sales to hospitals, clinics, pharmacies, and distributors, as well as public procurement (licitações).
2. Diagnostic Products: Roche Diagnóstica provides diagnostic solutions and testing products. Revenue generated through sales to healthcare institutions, laboratories, and direct customer service channels.
3. Diabetes Care Products: Roche Diabetes Care offers blood glucose monitoring products under the Accu-Chek brand. Revenue from sales of monitoring devices and consumables through pharmacies, direct customer service, and distributors.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

Roche develops and supplies innovative pharmaceutical medicines for oncology, immuno-oncology, neuroscience, rare diseases, and ophthalmology, alongside in-vitro diagnostic testing products and Accu-Chek diabetes care solutions. The company combines pharmaceutical and diagnostic capabilities to deliver personalized healthcare, selling through hospitals, clinics, pharmacies, distributors, and public procurement channels in Brazil.

Product overview

Roche operates as an integrated healthcare company offering pharmaceutical products and medical diagnostics. The pharmaceutical division provides innovative medications across oncology, immunology, neuroscience, rare diseases, and ophthalmology, including key products like Avastin, Herceptin, Tecentriq, Ocrevus, and Vabysmo. The diabetes care division focuses on the Accu-Chek brand of blood glucose monitoring products, including the recently launched Accu-Chek SmartGuide AI-enabled CGM solution. The diagnostics division provides laboratory and point-of-care diagnostic solutions. Roche's portfolio emphasizes personalized medicine, combining pharmaceutical and diagnostic capabilities.

Differentiator

Problem solved

Functional benefit

Brands

• Accu-Chek: Blood glucose monitoring devices and diabetes care solutions
• Roche Dialogo
• Conexão Roche
• Mulher Consciente
• Visionaries

Products and services

• Actemra (tocilizumabe) Monoclonal antibody medication indicated for autoimmune diseases, prescribed by physicians and dispensed through pharmacies and hospitals.
• Alecensa (cloridrato de alectinibe) Tyrosine kinase inhibitor indicated for ALK-positive non-small cell lung cancer, sold to hospitals and oncology specialists.
• Avastin (bevacizumabe) Anti-angiogenic therapy indicated for various cancers including colorectal, lung, and breast cancer.
• Ocrevus (ocrelizumabe) Monoclonal antibody indicated for multiple sclerosis and neuromyelitis optica spectrum disorder, sold to neurology specialists and hospitals.
• Hemcibra (emicizumabe) Bispecific monoclonal antibody indicated for hemophilia A, sold to hematology specialists and hospitals.
• Herceptin (trastuzumabe) Monoclonal antibody indicated for HER2-positive breast cancer and gastric cancer, sold to oncology specialists and hospitals. Discontinuation of 150 mg IV importation to Brazil notified on 2026-02-10 due to lack of market demand.
• Tecentriq (atezolizumabe) PD-L1 inhibitor indicated for various cancers including lung, bladder, and breast cancer.
• Vabysmo (faricimabe) Bispecific antibody indicated for ophthalmology conditions including neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).
• Evrysdi (risdiplam) SMN2 splicing modifier indicated for spinal muscular atrophy.
• Enspryng (satralizumabe) Monoclonal antibody indicated for neuromyelitis optica spectrum disorder (NMOSD).
• Phesgo (pertuzumabe + trastuzumabe) Fixed-dose combination indicated for HER2-positive breast cancer.
• Accu-Chek SmartGuide AI-enabled continuous glucose monitoring solution with predictive hypoglycemia algorithms for adults with type 1 and type 2 diabetes on flexible insulin therapy.
• Accu-Chek Blood Glucose Monitoring Products Blood glucose monitoring devices and consumables sold under the Accu-Chek brand through pharmacies, distributors, and direct customer service for people with diabetes.
• Roche Diagnostic Solutions In-vitro diagnostic tests, reagents, and laboratory/point-of-care diagnostic solutions supplied to laboratories, hospitals, and healthcare institutions.

Quantifiable outcome

• 9.2% MARD accuracy for Accu-Chek SmartGuide CGM solution
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature2 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• INAME (Instituto Nacional de Atrofia Muscular Espinhal)coreStrategic or Co-development Partner · 12 August 2025Partnership with INAME for 'Um Olhar sobre a AME tipo III no Brasil' research initiative conducted by VEJA SAÚDE with Roche support, collecting data from over 120 participants.
• IQVIA LtdcoreImplementation/ SI/ Consulting PartnerIQVIA Ltd provides IT support, maintenance, and business continuity services for Roche's technology infrastructure. Located at 210 Pentonville Road, London N1 9JY, England, UK.
• The Valuable 500minorStrategic or Co-development PartnerRoche made a public commitment to The Valuable 500, an organization with the mission to use the power of business to promote lasting change for 1.3 billion people worldwide living with disabilities.
• Instituto OncoguiacoreStrategic or Co-development PartnerPartnership with Instituto Oncoguia to produce video series addressing the role of patient associations in cancer patient journeys. Content covers access to associations, welcoming and support networks, treatment quality, and patient rights.
• Femama (Federação Brasileira de Instituições Filantrópicas de Apoio à Saúde da Mama)coreStrategic or Co-development PartnerPartnership in the 'Um Olhar Sobre o Câncer de Mama no Brasil' research initiative, conducted by Editora Abril with Roche support, surveying 1,237 breast cancer patients.
• PEV Consultoria em SaúdeminorStrategic or Co-development PartnerRoche Farma partnered with PEV Consultoria em Saúde to develop an e-book on real-world health data in Latin America, coordinating with health technology assessment specialists.
• Retina BrasilminorStrategic or Co-development PartnerPartnership with Retina Brasil and FGV CPDOC for research on patient perception of AMD and diabetic macular edema, supported by Roche Brasil.
• INAME (Instituto Nacional de Atrofia Muscular Espinhal)coreStrategic or Co-development PartnerPartnership for 'Retrato da AME no Brasil' research initiative, a quantitative study conducted with 144 respondents including people with SMA and caregivers.
• Grupo Mulheres do Brasil and eCycleminorStrategic or Co-development PartnerSupport for the '#NaoUsouDescartou' initiative to help find medication disposal locations, supported by Grupo Mulheres do Brasil and eCycle.

Scale indicators6 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• Johnson & Johnson (Innovative Medicine): Major oncology and immunology pharma peer (Darzalex, Tremfya, Erleada) with comparable scale and similar GTM motion targeting specialists and hospitals.
• Pfizer: Global pharma major with significant oncology and rare-disease franchises (Seagen). Comparable scale, broad therapeutic-area coverage, and similar GTM motion via hospitals and physician channels.
• AstraZeneca: Global pharma peer with major oncology (Tagrisso, Imfinzi, Enhertu) and rare-disease franchises. Competes directly with Roche in lung cancer and other oncology indications.
• Sanofi: Global pharma peer with overlapping immunology (Dupixent), rare disease, and oncology franchises. Comparable scale and breadth, including diabetes care historically.
• Novartis: Global pharmaceutical peer with overlapping oncology, neuroscience, and immunology portfolios. Novartis operates at similar scale with comparable therapeutic-area breadth and is a direct competitor in multiple indications.
• Eli Lilly: Major pharma peer with oncology, neuroscience, and diabetes (Mounjaro) franchises. Increasingly direct competition in diabetes and immunology as Lilly expands in endocrinology.
• Merck & Co. (MSD): Direct competitor in oncology (Keytruda competes with Tecentriq), with a similarly broad pharmaceutical portfolio. Comparable scale and pipeline depth in immuno-oncology.
• Abbott: Direct competitor in diabetes care (FreeStyle Libre CGM) and diagnostics. Operates the dominant CGM franchise globally, putting pressure on Roche's Accu-Chek SmartGuide launch.

Regional players

• Bio-Rad Laboratories: Diagnostics peer with overlapping clinical-diagnostics product lines. Smaller scale than Roche Diagnostics but competes in similar hospital and laboratory channels.

Direct peers

• Dexcom: CGM specialist and the leading competitor in the continuous glucose monitoring category. Directly competes with Accu-Chek SmartGuide for the same patient and prescriber base in diabetes management.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@rochebrasil2805/featured
• Facebookfacebook.com/RocheBrasil
• Instagraminstagram.com/rochebrasil

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Roche